Bold Therapeutics Successfully Completes Phase 1b Trial and Advances into Global Phase 2 Trial of BOLD-100 in the Treatment of Advanced GI Cancers

Since its founding in mid-2018, Bold Therapeutics has made rapid and efficient progress. Today, Bold Therapeutics’ BOLD-100 advances into a global Phase 2 trial in the treatment of advanced GI cancers, among the most difficult-to-treat and refractory solid tumours with a mean survival time of only 5-7 months. We are optimistic that outcomes will be meaningfully improved by adding BOLD-100 to patients’ existing treatment regimens. We look forward to interim Phase 2 data by year-end 2022.

Read more here.